IFN-α and the combined therapy decreased protein levels of MMP-2,XIAP, OPN, and VEGF in the HCC lines HepG2, MHCC97L, and HCCLM3 compared withthe expression levels of the control group. The gene discussed is IFNA17; the disease is hepatocellular carcinoma.